PT - JOURNAL ARTICLE AU - Yan, Huadong AU - Valdes, Ana M AU - Vijay, Amrita AU - Wang, Shanbo AU - Liang, Lili AU - Yang, Shiqing AU - Wang, Hongxia AU - Tan, Xiaoyan AU - Du, Jingyuan AU - Jin, Susu AU - Huang, Kecheng AU - Jiang, Fanrong AU - Zhang, Shun AU - Zheng, Nanhong AU - Hu, Yaoren AU - Cai, Ting AU - Aithal, Guruprasad P. TI - Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study AID - 10.1101/2020.04.24.20077875 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.24.20077875 4099 - http://medrxiv.org/content/early/2020/09/07/2020.04.24.20077875.short 4100 - http://medrxiv.org/content/early/2020/09/07/2020.04.24.20077875.full AB - The study aimed to investigate whether specific medications used in the treatment chronic diseases affected either the development and/ or severity of COVID-19 in a cohort of 610 COVID-19 cases and 48,667 population-based controls from Zheijang, China. Using a cohort of 578 COVID-19 cases and 48,667 population-based controls from Zheijang, China we tested the role of usage of cardiovascular, antidiabetic and other medications on risk and severity of COVID 19. Analyses were adjusted for age, sex and BMI and for presence of relevant comorbidities. Individuals with hypertension taking calcium channel blockers had significantly increased risk [odds ratio (OR)= 1.73 (95% CI 1.2-2.3)] of manifesting symptoms of COVID-19 whereas those taking angiotensin receptor blockers and diuretics had significantly lower disease risk (OR=0.22; 95%CI 0.15-0.30 and OR=0.30; 95%CI 0.19-0.58 respectively). Among those with type 2 diabetes, dipeptidyl peptidase-4 inhibitors (OR= 6.02; 95% CI 2.3-15.5) and insulin (OR= 2.71; 95% CI 1.6-5.5) were more and glucosidase inhibitors were less prevalent (OR= 0.11; 95% CI 0.1-0.3) among with COVID-19 patients.Drugs used in the treatment of hypertension and diabetes influence the risk of development of COVID-19, but, not its severity.What is the current knowledge on the topic?Cardiovascular disease and Diabetes have been highlighted as comorbidities contributing to a more severe form of COVID-19 and medication to treat them may also influence the risk of COVID-19 and its clinical outcomes.What question did this study address?Does specific medications used in the treatment of chronic diseases influence the risk for the susceptibility to SARS CoV-2 infection of severity of COVID-19?What does this study add to our knowledge?The study confirms that higher BMI, diabetes and cardio/ cerebrovascular disease as independent risk factors for the development of COVID-19. Angtiotensin Receptor Blockers (ARBs) and diuretics were associated with reduced risk and Calcium Channel Blockers (CCBs) with increased risk of developing COVID-19. Among those with type 2 diabetes, dipeptidyl peptidase-4 and were associated with increased and glucosidase inhibitors with reduced risk development of COVID-19. None of the antihypertensive or anti-diabetic drugs were associated with increased risk of severe or critical form of the infection.Drugs used in the treatment of hypertension and diabetes influence the risk of development of COVID-19, but are not associated with severity of the disease.How might this change clinical pharmacology or translational science?Findings from the current large case-control study confirmed no evidence to alter ARBs or ACEIs therapy in the context of COVID-19 severity in clinical practice. Hypertension significantly increases the risk of severe or critical SARS-CoV-2 infection indicating that carefully controlled blood pressure should be a priority to reduce the healthcare burden of COVID-19.Competing Interest StatementGPA is an advisory board member for Amryt Pharmaceuticals, Astra Zeneca, GSK, and Pfizer. AMV is a consultant for Zoe Global Ltd and member of the scientific advisory board of CPKelco. Funding StatementFunded by the Social Development Major Projects of Ningbo City (2016C51005), Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2018ZD039), Zhejiang Provincial natural science foundation (LGF20H030006) and by the NIHR Nottingham Biomedical Research Centre (Reference no: BRC-1215-20003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The local ethics committees of all hospitals approved the retrospective study of cohorts COVID-19.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the current analysis will be made available on request. The data has currently not been uploaded on a repository or online database.